Company news

Kairos Pharma, Ltd. news in 2026

Kairos Pharma, Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology

November 5, 2026

Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development

November 3, 2026

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

October 6, 2026

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026

Kairos Pharma Announces 1-for-7 Reverse Stock Split

August 21, 2026

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

July 22, 2026

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

July 15, 2026

Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders

June 4, 2026

Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award

May 14, 2026

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

May 13, 2026

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

May 8, 2026

Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

April 15, 2026

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

March 2, 2026

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

February 26, 2026

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

January 20, 2026

Decks in 2026